4-Chloro-2,6-dibromotoluene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Chloro-2,6-dibromotoluene
• 英文别名: 1,3-dibromo-5-chloro-2-methylbenzene
• 化学式: C₇H₅Br₂Cl
• 分子量: 284.37
• InChiKey: WUHITJWZONUGGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  3,5-二溴-4-甲基苯胺 在 2-甲基-2-丁烯 、 2-乙基己基硝酸酯 、 四丁基氯化铵 、 copper(l) chloride 作用下， 以 乙腈 为溶剂， 以40 %的产率得到4-Chloro-2,6-dibromotoluene
  参考文献：
  名称：

  硝酸盐还原使芳基重氮化学更加安全

  摘要：

  芳基重氮盐仍然是有机合成的主要成分，并且仍然主要按照 19 世纪制定的方案进行制备。由于其他芳基（拟）卤化物通常无法实现良好的反应性，因此重氮化学不断发展。氮气的轻松挤出有助于实现所需的反应性，但也是安全问题的原因。自从这些试剂被发现以来，爆炸事件时有发生，并且仍然会导致事故。在这项研究中，我们报告了基于使用硫代硫酸盐或二卤代铜酸盐作为电子供体的硝酸盐还原的重氮化学范式转变，从而避免了重氮积累。由于硝酸盐还原是速率限制的，因此芳基重氮盐作为短暂的中间体产生，这使得苯胺一步即可实现更安全且通常更有效的脱氨卤化。

  DOI：

  10.1126/science.adn7006

文献信息

• Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists
  申请人：Nakazato Atsuro

  公开号：US20080280928A1

  公开（公告）日：2008-11-13

  [PROBLEM TO BE SOLVED] An object of the present invention is to provide an antagonist against CRF receptors and/or an agonist for δ receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. [SOLUTION] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following a [I] has a high affinity for CRF receptors and/or δ receptors, and is effective against diseases in which CRF is considered to be involved.

  【问题需解决】本发明的目的是提供一种针对CRF受体的拮抗剂和/或δ受体的激动剂，其作为治疗或预防CRF参与的疾病，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物依赖、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、癫痫、皮炎、精神分裂症、疼痛等方面的治疗或预防药物。 【解决方案】一种通过以下a[I]所代表的环状氨基基团取代的吡咯吡嘧啶或吡咯吡啶衍生物具有高亲和力，可用于CRF受体和/或δ受体，并对CRF参与的疾病具有治疗作用。
• Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group
  申请人：NAKAZATO Atsuro

  公开号：US20080287397A1

  公开（公告）日：2008-11-20

  An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  本发明的目的是提供一种CRF受体拮抗剂，作为治疗或预防与CRF有关的疾病的药物，例如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮炎、精神分裂症等。这个问题可以通过下式[I]所表示的带有环状氨基基团的吡咯吡嘧啶或吡咯吡啶衍生物来解决，其具有高亲和力，对CRF受体有效，并且对与CRF有关的疾病也有效。
• Olefin polymerization catalyst system useful for polar monomers
  申请人：Baugh Sauders Lisa

  公开号：US20070197751A1

  公开（公告）日：2007-08-23

  This invention relates to copolymers produced by a polymerization method comprising contacting at least one olefin monomer, at least one polar monomer, an optional activator, and a catalyst compound represented by the formula: wherein M is selected from groups 3-11 of the periodic table; L 1 represents a formal anionic ligand, L 2 represents a formal neutral ligand, a is an integer greater than or equal to 1; b is greater than or equal to 0; c is greater than or equal to 1, E is nitrogen or phosphorus, Ar 0 is arene, R 1 -R 4 are, each independently, selected from hydrogen, hydrocarbyl, substituted hydrocarbyl or functional group, provided however that R 3 and R 4 do not form a naphthyl ring, N is nitrogen and O is oxygen.

  本发明涉及通过聚合方法制备的共聚物，该方法包括接触至少一种烯烃单体、至少一种极性单体、可选的活化剂和催化剂化合物。该催化剂化合物的化学式为：其中M从周期表的3-11组中选择；L1表示正离子配体，L2表示中性配体，a是大于等于1的整数；b大于等于0；c大于等于1；E是氮或磷，Ar0是芳烃，R1-R4分别选择自氢、烃基、取代烃基或功能基，但R3和R4不形成萘环，N是氮，O是氧。
• PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS
  申请人：NAKAZATO Atsuro

  公开号：US20110124862A1

  公开（公告）日：2011-05-26

  [Problem to be Solved] An object of the present invention is to provide an antagonist against CRF receptors and/or an agonist for δ receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. [Solution] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following formula [I] has a high affinity for CRF receptors and/or δ receptors, and is effective against diseases in which CRF is considered to be involved.

  【待解决的问题】本发明的目的是提供一种CRF受体的拮抗剂和/或δ受体的激动剂，作为治疗或预防CRF参与的疾病（如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈病、进食障碍、高血压、胃肠疾病、药物依赖、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、癫痫、皮炎、精神分裂症、疼痛等）的有效药物。 【解决方案】以下式[I]所表示的带有环状氨基基团的吡咯吡嘧啶或吡咯吡啶衍生物具有高亲和力，可作为CRF受体和/或δ受体的拮抗剂，对于CRF参与的疾病具有治疗效果。
• PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP
  申请人：NAKAZATO Atsuro

  公开号：US20110130364A1

  公开（公告）日：2011-06-02

  An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  本发明的目的是提供一种CRF受体拮抗剂，该拮抗剂作为治疗或预防CRF参与的疾病的药物，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮炎、精神分裂症等方面有效。这个问题可以通过一种代表式[I]下的带有环状氨基基团的吡咯吡咪啉或吡咯吡啶衍生物来解决，该衍生物对CRF受体具有高亲和力，并对CRF参与的疾病有效。